Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2022-07-15 Regulatory Filings
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Resolution the Labor Strike at the Company’s Manufacturing Facility in Israel
Regulatory Filings Classification · 1% confidence The document is very short (2003 characters) and explicitly states, 'Attached hereto is a report on...' followed by a file name. This structure indicates that the document itself is an announcement about the publication of another report, rather than the full report content. The filing is made to the Israel Securities Authority and Tel Aviv Stock Exchange under 'Immediate Report Regulation 4 of the Securities Regulations...'. Since the content is an announcement of an event (resolution of a labor strike and signing of an agreement) and it points to an attached document, it fits the criteria for a general regulatory announcement that doesn't fit a more specific category like ER, 10-K, or IR. Therefore, the most appropriate classification based on the 'MENU VS MEAL' rule and the nature of the filing is Regulatory Filings (RNS), as it is a general, immediate regulatory disclosure.
2022-07-15 English
Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement
Regulatory Filings Classification · 1% confidence The document is a Form 6-K filed with the SEC by Kamada Ltd. It serves as a regulatory filing to announce a specific business development: an $11.4 million international procurement agreement for the product VARIZIG. While it contains a press release, the document itself is a formal SEC filing (Form 6-K) used to disclose material information to the public. Since it does not fit into specific categories like 'Earnings Release' (it is a contract announcement) or 'M&A' (it is a supply agreement), it falls under the 'Regulatory Filings' (RNS) category as the standard fallback for SEC 6-K filings that report miscellaneous material events.
2022-07-06 English
Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement
Report Publication Announcement Classification · 1% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange (TASE). It announces a specific event ('Kamada Announces $11.4 Million International VARIZIG Procurement Agreement') and explicitly states, 'Attached hereto is a report on*Kamada Announces $11.4 Million International VARIZIG Procurement Agreement* *ea162494-6k_kamadaEDGAR1_Bannerless_isa.pdf'. This structure—a brief announcement referencing an attached document—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule, as it is announcing the release of a more detailed report rather than being the detailed report itself. The length (1868 chars) also supports this being an announcement.
2022-07-06 English
Registration Statement on Form S-8
Share Issue/Capital Change Classification · 1% confidence The document explicitly states it is a "FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933" filed by KAMADA LTD. Form S-8 is used by companies to register securities that are to be offered to employees, directors, consultants, or advisors under employee benefit plans. This filing relates to the registration of ordinary shares issuable under the '2011 Israeli Share Award Plan'. While the document references the Annual Report (Form 20-F) for incorporation by reference, the primary purpose and classification of this document itself is the registration of securities for an employee plan, which is a specific type of SEC filing not explicitly listed in the provided definitions (AGM-R, 10-K, AR, etc.). However, Form S-8 is a core registration document related to capital structure and employee compensation plans. Given the options, this filing is most closely related to the issuance of shares under a plan, which falls under the broader category of capital/financing activities or share issuance. Since the document is a formal SEC registration statement for shares to be issued under an employee plan, it is a filing related to capital structure changes or share issuance. The closest fit among the provided codes that deals with share issuance/capital structure is 'CAP' (Capital/Financing Update) or 'SHA' (Share Issue/Capital Change). Since this is a registration statement for shares to be issued under an employee plan, 'SHA' (Share Issue/Capital Change) is the most precise fit for the underlying action being registered, although 'CAP' is also plausible. Since Form S-8 is a registration for the issuance of shares, SHA is selected. If SHA were not available, CAP would be the next best fit. Given the context of SEC filings, this is a specific registration, not a general announcement, so RPA/RNS is incorrect. SHA is the best fit for registering shares for issuance.
2022-06-28 English
Registration Statement on Form S-8
Regulatory Filings Classification · 1% confidence The document explicitly states, 'Kamada Ltd. is filing this Registration Statement on Form S-8' and 'Attached hereto is a report on*Kamada Ltd. is filing this Registration Statement on Form S-8* ea161899-s8_kamadaltdEDGAR_Bannereless_isa.pdf'. A Form S-8 is a registration statement related to employee stock option plans, which falls under capital structure or financing activities, but the document itself is a brief regulatory notification (Immediate Report) announcing the filing of the S-8 form, not the S-8 form content itself. Given the short length (1843 chars) and the nature of announcing a filing rather than containing the full report, it is best classified as a general Regulatory Filing (RNS) or potentially Capital/Financing Update (CAP). Since S-8 relates to securities/capital structure, CAP is a strong candidate, but RNS is the fallback for miscellaneous regulatory announcements that don't fit the primary definitions. However, since the core subject is the registration of securities/options, CAP is more specific than RNS. Let's re-evaluate the definitions. None of the definitions perfectly match 'Registration Statement on Form S-8'. Form S-8 relates to employee compensation plans, which is a form of capital change/financing. Given the options, 'CAP' (Capital/Financing Update) is the closest fit for a registration statement concerning employee stock plans, although 'RNS' is a safe fallback. Since it is a formal regulatory filing announcing a specific action related to securities, and 'CAP' covers financing activities, I will select CAP.
2022-06-28 English
Kamada Strengthens Senior Leadership Team; Furthering Commitment as a Fully Integrated Global Leader in the Specialty Plasma Derived Therapeutics Market
Board/Management Information Classification · 1% confidence The document is explicitly titled "FORM 6-K" and is filed with the SEC. Form 6-K is used by Foreign Private Issuers to report material information that is made public in their home country or required to be filed with a foreign securities exchange. The exhibit attached (99.1) is an announcement regarding senior leadership team promotions, which constitutes material information about management changes. This type of announcement, when filed on Form 6-K, is generally classified as Board/Management Information (MANG) if the focus is purely on the personnel change, or sometimes as a general Regulatory Filing (RNS) if the 6-K itself is the primary document type being tracked. However, given the specific definitions, the content (promotions of VP roles) directly aligns with 'Board/Management Information' (MANG). Since the document is a full filing (Form 6-K) containing the material information, and not just an announcement *about* a report (which would be RPA/RNS), MANG is the most specific fit for the content, although RNS is the code for the SEC form type itself if no other category fits. Since MANG is a specific category for management changes, it takes precedence over the general RNS fallback for the content type. The document length is substantial (6878 chars), indicating it is the full report, not just a brief announcement of a report.
2022-06-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.